Drug Trial Radar · NCT00676507
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy
Last checked: Nov 20, 2026Latest source record: May 8, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
532
Actual
Start
Jul 2008
Primary completion
Jan 2013
Study completion Jan 2013
Sponsor
- Lead sponsor
- NovaRx CorporationIndustry
- Sponsor type
- Industry
- First posted
- May 13, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rationale: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. It is not yet known whether vaccine therapy is more effective than a placebo as maintenance therapy in treatment of subjects with non-small cell lung cancer. Purpose: This randomized phase III trial is studying vaccine therapy to see how well it works compared with a placebo in treating subjects with stage III or stage IV non-small cell lung cancer.
Conditions
- Lung Neoplasm
- Carcinoma Non-small Cell Lung Cancer Stage IIIA
- Carcinoma Non-small Cell Lung Cancer Stage IIIB
- Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions
Lucanix™Biological
Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
Placebo ComparatorOther
Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare the overall survival of subjects with stage III or IV non-small cell lung cancer treated with belagenpumatucel-L (Lucanix™) vs placebo.Time frame: 7 years
Locations
82 sites in 8 countries. Site status is shown where the registry gives one.
Southern Cancer Center
Mobile, Alabama
Alaska Regional Hospital
Anchorage, Alaska
Mayo Clinic Cancer Center
Scottsdale, Arizona
Clopton Clinic Hematology/Oncology
Jonesboro, Arkansas
Comprehensive Blood and Cancer Center
Bakersfield, California
University of California, San Diego
La Jolla, California
UCLA Pasadena Oncology
Pasadena, California
Cancer Care Associates
Redondo, California
Innovative Research Center of California
San Diego, California
Sansum Clinic
Santa Barbara, California
Santa Barbara Hematology Oncology Medical Group, Inc.
Santa Barbara, California
Central Coast Medical Oncology Corporation
Santa Maria, California
UCLA Cancer Center
Santa Monica, California
UCLA Cancer Center-Valencia
Valencia, California
UCLA Cancer Center
Westlake Village, California
University of Colorado Health Science Center
Aurora, Colorado
Pasco Hernando Oncology Associates, P.A.
Brooksville, Florida
Medical Specialist of Palm Beaches
Lake Worth, Florida
Ocala Oncology
Ocala, Florida
Space Coast Medical Center
Titusville, Florida
Atlanta Cancer Care
Roswell, Georgia
Kootenai Cancer Center
Coeur d'Alene, Idaho
St. Francis Medical Group Oncology and Hematology Specialists
Indianapolis, Indiana
Iowa Blood and Cancer Center
Cedar Rapids, Iowa
James Graham Brown Cancer Center
Louisville, Kentucky
Hematology Oncology Life Center
Alexandria, Louisiana
National Cancer Institute Center for Cancer Research, Medical Oncology Branch
Bethesda, Maryland
Henry Ford Health System
Detroit, Michigan
University of Minnesota Medical Center
Minneapolis, Minnesota
Mayo Clinic Cancer Center
Rochester, Minnesota
University of Tennessee Cancer Institute
Southaven, Mississippi
Comprehensive Cancer Centers of Nevada
Henderson, Nevada
Comprehensive Cancer Centers of Nevada
Henderson, Nevada
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Richmond University Medical Center
Staten Island, New York
Eastchester Center for Cancer Care
The Bronx, New York
Allergy Partners of West North Carolina
Asheville, North Carolina
Cancer Care of WNC
Asheville, North Carolina
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.